DODanae Olaso

Danae Olaso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Danae Olaso has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig

    by Miriam Manook, Danae Olaso, Imran Anwar, Isabel DeLaura, Janghoon Yoon, Yeeun Bae, Andrew Barbas, Brian Shaw, Dimitrios Moris, Mingqing Song, et al.

    Genetic modification of porcine donors, combined with optimized immunosuppression, has been shown to improve outcomes of experimental xenotransplant. However, little is known about outcomes in sensitized recipients, a population that could potentially benefit the most from the clinical implementation of xenotransplantation. Here, five highly allosensitized rhesus macaques received a porcine kidney from GGTA1 (α1,3-galactosyltransferase) knockout pigs expressing the human CD55 transgene (1KO.1TG) and were maintained on an anti-CD154 monoclonal antibody (mAb)–based immunosuppressive regimen. These recipients developed de novo xenoreactive antibodies and experienced xenograft rejection with evidence of thrombotic microangiopathy and antibody-mediated rejection (AMR). In comparison, three highly allosensitized rhesus macaques receiving a kidney from GGTA1 , CMAH (cytidine monophospho- N -acetylneuraminic acid hydroxylase), and b4GNT2 / b4GALNT2 (β-1,4- N -acetyl-galactosaminyltransferase 2) knockout pigs expressing seven human transgenes including human CD46 , CD55 , CD47 , THBD (thrombomodulin), PROCR (protein C receptor), TNFAIP3 (tumor necrosis factor–α–induced protein 3), and HMOX1 (heme oxygenase 1) (3KO.7TG) experienced significantly prolonged graft survival and reduced AMR, associated with dampened post-transplant humoral responses, early monocyte and neutrophil activation, and T cell repopulation. After withdrawal of all immunosuppression, recipients who received kidneys from 3KO.7TG pigs rejected the xenografts via AMR. These data suggest that allosensitized recipients may be suitable candidates for xenografts from genetically modified porcine donors and could benefit from an optimized immunosuppression regimen designed to target the post-transplant humoral response, thereby avoiding AMR.


  • Open Access

    Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant

    by Miriam Manook, Danae Olaso, Imran J. Anwar, Janghoon Yoon, Isabel Delaura, Yeeun Bae, Dimitrios Moris, Brian Shaw, Mingqing Song, Alton B. Farris, et al.

    Among sensitized patients awaiting a transplant, females are disproportionately represented, partly because of pregnancy-induced sensitization. Using female NHPs sensitized by pregnancy alone, we examined the efficacy of costimulation blockade and proteasome inhibition for desensitization. Three animals received no desensitization (control), and seven animals received weekly carfilzomib (27 mg/m 2 ) and belatacept (20 mg/kg) before kidney transplantation. All animals received renal allografts from crossmatch-positive/maximally MHC-mismatched donors. Controls and three desensitized animals received tacrolimus-based immunosuppression. Four desensitized animals received additional belatacept with tacrolimus-based immunosuppression. Multiparous females had less circulating donor-specific antibody when compared to skin-sensitized males before transplantation. While females receiving desensitization showed only a marginal survival benefit over control females (MST = 11 days versus 63 days), additional belatacept to posttransplant maintenance significantly prolonged graft survival (MST > 164 days) and suppressed posttransplant DSA and circulating follicular helper T-like cells. This combination of therapies demonstrates great potential to reduce antibody-mediated rejection in sensitized recipients.


  • Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates

    by Robin Schmitz, Zachary W. Fitch, Miriam Manook, Paul M. Schroder, Ashley Y. Choi, Danae Olaso, Janghoon Yoon, Yeeun Bae, Brian I. Shaw, Mingqing Song, et al.

    Key Points: Belatacept-based maintenance immunosuppression prevents antibody-mediated rejection and enables long-term kidney allograft survival in sensitized nonhuman primate recipients. Post-transplant belatacept prevents the rebound of follicular helper T cells, class-switched B cells, and antibody-secreting cells. Additional belatacept with tacrolimus increases the risk of viral reactivation and post-transplant lymphoproliferative disease. Preexisting donor-specific antibodies (DSA) to MHC antigens increase the risk of antibody-mediated rejection (AMR) in sensitized transplant recipients and reduces graft survival. Pretransplant desensitization with costimulation blockade and proteasome inhibition has facilitated transplantation in our preclinical nonhuman primate (NHP) model. However, long-term graft survival is limited by rebound of DSA after transplantation. In this study, we performed kidney transplants between highly sensitized, maximally MHC-mismatched NHPs (n=14). At kidney transplantation, primates received T cell depletion with rhesus-specific anti-thymocyte globulin (rhATG; n=10) or monoclonal anti-CD4 and anti-CD8 antibodies (n=4). Maintenance immunosuppression consisted of belatacept and tacrolimus (n=5) or belatacept and rapamycin (n=9) with steroids. Rebound of DSA post–kidney transplantation was significantly reduced compared with maintenance immunosuppression with tacrolimus, mycophenolate, and steroids. Protocol lymph node biopsy specimens showed a decrease in germinal center activity, with low frequencies of T follicular helper cells and class-switched B cells after kidney transplantation. Combined belatacept and rapamycin was superior in controlling viral reactivation, enabling weaning of ganciclovir prophylaxis. Tacrolimus was associated with increased morbidity that included cytomegalovirus and parvovirus viremia and post-transplant lymphoproliferative disorder. All primates in the tacrolimus/belatacept group failed discontinuation of antiviral therapy. Overall, belatacept-based immunosuppression increased AMR-free graft survival by controlling post-transplant humoral responses in highly sensitized NHP recipients and should be further investigated in a human clinical trial.


  • Same-teams versus different-teams for long distance lung procurement: A cost analysis

    by Danae G. Olaso, Samantha E. Halpern, Madison K. Krischak, Sandra Au, Ian R. Jamieson, John C. Haney, Jacob A. Klapper, Matthew G. Hartwig


  • Textbook surgical outcome in lung transplantation: Analysis of a US national registry

    by Madison K. Krischak, Sandra Au, Samantha E. Halpern, Danae G. Olaso, Dimitrios Moris, Laurie D. Snyder, Andrew S. Barbas, John C. Haney, Jacob A. Klapper, Matthew G. Hartwig

    Intro: Textbook surgical outcome (TO) is a novel composite quality measure in lung transplantation (LTx). Compared to 1‐year survival metrics, TO may better differentiate center performance, and motivate improvements in care. To understand the feasibility of implementing this metric, we defined TO in LTx using US national data, and evaluated its ability to predict post‐transplant outcomes and differentiate center performance.Methods: Adult patients who underwent isolated LTx between 2016 and 2019 were included. TO was defined as freedom from post‐transplant length of stay > 30 days, 90‐day mortality, intubation or extracorporeal membrane oxygenation at 72 h post‐transplant, post‐transplant ventilator support lasting ≥5 days, postoperative airway dehiscence, inpatient dialysis, pre‐discharge acute rejection, and grade 3 primary graft dysfunction at 72 h. Recipient and donor characteristics and post‐transplant outcomes were compared between patients who achieved and failed TO.Results: Of 8959 lung transplant recipients, 4664 (52.1%) achieved TO. Patient and graft survival were improved among patients who achieved TO (both log‐rank P < .0001). Among 62 centers, adjusted rates of TO ranged from 27.0% to 72.4% reflecting a wide variability in center‐level performance.Conclusion: TO defined using national data may represent a novel composite metric to guide quality improvement in LTx across US transplant centers.Summary: In this study we defined textbook outcome (TO) for lung transplantation (LTx) using US national data. We found that achievement of TO was associated with improved post‐transplant survival, and wide variability in center‐level LTx performance. These findings suggest that TO could be readily implemented to compare quality of care among US LTx centers.


  • Open Access

    Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient

    by Danae Olaso, Miriam Manook, Dimitrios Moris, Stuart Knechtle, Jean Kwun

    Patients with previous sensitization events against anti-human leukocyte antigens (HLA) often have circulating anti-HLA antibodies. Following organ transplantation, sensitized patients have higher rates of antibody-mediated rejection (AMR) compared to those who are non-sensitized. More stringent donor matching is required for these patients, which results in a reduced donor pool and increased time on the waitlist. Current approaches for sensitized patients focus on reducing preformed antibodies that preclude transplantation; however, this type of desensitization does not modulate the primed immune response in sensitized patients. Thus, an optimized maintenance immunosuppressive regimen is necessary for highly sensitized patients, which may be distinct from non-sensitized patients. In this review, we will discuss the currently available therapeutic options for induction, maintenance, and adjuvant immunosuppression for sensitized patients.


  • Open Access

    Lung transplantation after ex vivo lung perfusion versus static cold storage: An institutional cost analysis

    by Samantha E. Halpern, Samuel J. Kesseli, Sandra Au, Madison K. Krischak, Danae G. Olaso, Haley Smith, Greg Tipton, Ian R. Jamieson, Andrew S. Barbas, John C. Haney, et al.